Pharmacogenetics of asthma therapy

Current Pharmaceutical Design

Volumn 15, Issue 32, 2009, Pages 3742-3753

  Qing, Ling Duan ^a   Tantisira, Kelan G ^a  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADENYLATE CYCLASE; ARACHIDONATE 5 LIPOXYGENASE; BECLOMETASONE; BETA 2 ADRENERGIC RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CD23 ANTIGEN; CORTICOSTEROID; CORTICOTROPIN RELEASING FACTOR RECEPTOR 1; CORTICOTROPIN RELEASING FACTOR RECEPTOR 2; CYSTEINY LEUKOTRIENE RECEPTOR 2; G PROTEIN COUPLED RECEPTOR; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR ALPHA; LEUKOTRIENE; LEUKOTRIENE A4 HYDROLASE; LEUKOTRIENE C4 SYNTHASE; LEUKOTRIENE RECEPTOR; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LIPOXYGENASE INHIBITOR; LONG ACTING DRUG; MULTIDRUG RESISTANCE PROTEIN 1; ORGANIC ANION TRANSPORTER 2; ORGANIC ANION TRANSPORTER 2B1; PROTEIN KINASE; SALBUTAMOL; SALMETEROL; SHORT ACTING DRUG; TRANSCRIPTION FACTOR T BET; UNCLASSIFIED DRUG;

ADRENAL SUPPRESSION; AMINO ACID SUBSTITUTION; ASTHMA; BONE DEMINERALIZATION; CATARACTOGENESIS; DOSAGE SCHEDULE COMPARISON; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG MEGADOSE; DRUG RECEPTOR BINDING; DRUG RESPONSE; DRUG TARGETING; FORCED EXPIRATORY VOLUME; GENETIC ASSOCIATION; GENETIC TRAIT; GENETIC VARIABILITY; GROWTH RETARDATION; HUMAN; LOW DRUG DOSE; NONHUMAN; PHARMACOGENETICS; PRIORITY JOURNAL; REVIEW; SIDE EFFECT; SINGLE NUCLEOTIDE POLYMORPHISM; SKIN MANIFESTATION; UNSPECIFIED SIDE EFFECT;

ADRENERGIC BETA-AGONISTS; ANIMALS; ANTI-ASTHMATIC AGENTS; ASTHMA; FORCED EXPIRATORY VOLUME; GENETIC VARIATION; GLUCOCORTICOIDS; HUMANS; LEUKOTRIENE ANTAGONISTS; PHARMACOGENETICS; PHENOTYPE;

EID: 70449628095     PISSN: 13816128     EISSN: None     Source Type: Journal    
DOI: 10.2174/138161209789649510     Document Type: Review

References (152)

1. Masoli M, Fabian D, Holt S, Beasley R. The global burden of asthma: executive summary of the GINA Dissemination Committee report. Allergy 2004; 59(5): 469-478 (Pubitemid 38580764)
2. Weiss KB, Gergen PJ, Wagener DK. Breathing better or wheezing worse? The changing epidemiology of asthma morbidity and mortality. Annu Rev Public Health 1993; 14: 491-513.
3. Mannino DM, Homa DM, Pertowski CA, Ashizawa A, Nixon LL, Johnson CA, et al. Surveillance for asthma - United States, 1960-1995. CDC surveillance summaries. Morb Mortal Wkly Rep 1998; 47(No.): 1-28.
4. Busse W, Banks-Schlegel S, Noel P, Ortega H, Taggart V, Elias J. Future research directions in asthma: an NHLBI Working Group report. Am J Respir Crit Care Med 2004; 170(6): 683-690 (Pubitemid 39202212)
5. American Lung Association Epidemiology and Statistics Unit. Trends in Asthma Morbidity and Mortality. New York: The American Lung Association 2007.
6. Drazen JM, Silverman EK, Lee TH. Heterogeneity of therapeutic responses in asthma. Br Med Bull 2000; 56(4): 1054-1070
7. Malmstrom K, Rodriguez-Gomez G, Guerra J, Villaran C, Pineiro A, Wei LX, et al. Oral montelukast, inhaled beclomethasone, and placebo for chronic asthma. A randomized, controlled trial. Montelukast/Beclomethasone Study Group. Ann Intern Med 1999; 130(6): 487-495
8. Lanes SF, Garcia Rodriguez LA, Huerta C. Respiratory medications and risk of asthma death. Thorax 2002; 57(8): 683-686 (Pubitemid 34864523)
9. Dunlop KA, Carson DJ, Shields MD. Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid. Pediatr Pulmonol 2002; 34(1): 85-86 (Pubitemid 34686717)
10. Kennedy MJ, Carpenter JM, Lozano RA, Castile RG. Impaired recovery of hypothalamic-pituitary-adrenal axis function and hypoglycemic seizures after high-dose inhaled corticosteroid therapy in a toddler. Ann Allergy Asthma Immunol 2002; 88(5): 523-526
11. Blumenthal MN. Genetics of Allergy and Asthma. In: Blumenthal MN, Björkstén B, Eds. Historical Persepectives. New York: Marcel Dekker Inc. 1997; pp. 1-18.
12. Nieminen MM, Kaprio J, Koskenvuo M. A population-based study of bronchial asthma in adult twin pairs. Chest 1991; 100(1): 70-75
13. Duffy DL, Martin NG, Battistutta D, Hopper JL, Mathews JD. Genetics of asthma and hay fever in Australian twins. Am Rev Respir Dis 1990; 142(6 Pt 1): 1351-1358
14. Levy D, DeStefano AL, Larson MG, O'Donnell CJ, Lifton RP, Gavras H, et al. Evidence for a gene influencing blood pressure on chromosome 17. Genome scan linkage results for longitudinal blood pressure phenotypes in subjects from the framingham heart study. Hypertension 2000; 36(4): 477-483
15. Florez JC, Hirschhorn J, Altshuler D. The inherited basis of diabetes mellitus: implications for the genetic analysis of complex traits. Annu Rev Genomics Hum Genet 2003; 4: 257-291 (Pubitemid 37392926)
16. Holt PG. Parasites, atopy, and the hygiene hypothesis: resolution of a paradox? Lancet 2000; 356(9243): 1699-1701
17. Cookson W. The alliance of genes and environment in asthma and allergy. Nature 1999; 402(6760 Suppl): B5-11. (Pubitemid 129517082)
18. Evans WE, Johnson JA. Pharmacogenomics: the inherited basis for interindividual differences in drug response. Annu Rev Genomics Hum Genet 2001; 2: 9-39. (Pubitemid 35264999)
19. Lemanske RF, Jr., Allen DB. Choosing a long-term controller medication in childhood asthma. The proverbial two-edged sword. Am J Respir Crit Care Med 1997; 156(3 Pt 1): 685-687
20. Wu AC, Tantisira K, Li L, Schuemann B, Weiss S. Repeatability of response to asthma medications. J Allergy Clin Immunol 2009; 123(2): 385-390
21. Wilk JB, Djousse L, Arnett DK, Rich SS, Province MA, Hunt SC, et al. Evidence for major genes influencing pulmonary function in the NHLBI family heart study. Genet Epidemiol 2000; 19(1): 81-94. (Pubitemid 30445639)
22. Palmer LJ, Burton PR, James AL, Musk AW, Cookson WO. Familial aggregation and heritability of asthma-associated quantitative traits in a population-based sample of nuclear families. Eur J Hum Genet 2000; 8(11): 853-860
23. Vesell ES. Pharmacogenetic perspectives gained from twin and family studies. Pharmacol Ther 1989; 41(3): 535-552
24. Coleman MD. Factors affecting drug metabolism. Human Drug Metabolism: John Wiley & Sons 2005: 131-162
25. Kalow W, Tang BK, Endrenyi L. Hypothesis: comparisons of inter- and intra-individual variations can substitute for twin studies in drug research. Pharmacogenetics 1998; 8(4): 283-289 (Pubitemid 28372321)
26. Szefler SJ, Phillips BR, Martinez FD, Chinchilli VM, Lemanske RF, Strunk RC, et al. Characterization of within-subject responses to fluticasone and montelukast in childhood asthma. J Allergy Clin Immunol 2005; 115(2): 233-242
27. Raby BA, Weiss ST. Beta2-adrenergic receptor genetics. Curr Opin Mol Ther 2001; 3(6): 554-566
28. Osler W. The Principles and Practices of Medicine. New York: D. Appleton-Century Company 1942.
29. Inman WH, Adelstein AM. Rise and fall of asthma mortality in England and Wales in relation to use of pressurised aerosols. Lancet 1969; 2(7615): 279-285
30. Sears MR. Relationships between asthma mortality and treatment. Ann Allergy 1993; 70(5): 425-426
31. Lazarus SC, Boushey HA, Fahy JV, Chinchilli VM, Lemanske RF, Jr., Sorkness CA, et al. Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent asthma: a randomized controlled trial. JAMA 2001; 285(20): 2583-2593 (Pubitemid 32479898)
32. Lemanske RF, Jr., Sorkness CA, Mauger EA, Lazarus SC, Boushey HA, Fahy JV, et al. Inhaled corticosteroid reduction and elimination in patients with persistent asthma receiving salmeterol: a randomized controlled trial. JAMA 2001; 285(20): 2594-2603 (Pubitemid 32479899)
33. Greening AP, Ind PW, Northfield M, Shaw G. Added salmeterol versus higher-dose corticosteroid in asthma patients with symptoms on existing inhaled corticosteroid. Allen & Hanburys Limited UK Study Group. Lancet 1994; 344(8917): 219-224 (Pubitemid 24229008)
34. Pauwels RA, Lofdahl CG, Postma DS, Tattersfield AE, O'Byrne P, Barnes PJ, et al. Effect of inhaled formoterol and budesonide on exacerbations of asthma. Formoterol and Corticosteroids Establishing Therapy (FACET) International Study Group. The N Eng J Med 1997; 337(20): 1405-1411
35. Hawkins GA, Tantisira K, Meyers DA, Ampleford EJ, Moore WC, Klanderman B, et al. Sequence, haplotype, and association analysis of ADRbeta2 in a multiethnic asthma case-control study. Am J Respir Crit Care Med 2006; 174(10): 1101-1109 (Pubitemid 44772080)
36. Ortega VE, Montealegre F, Chardon D, Meyers DA, Diallo AF, Bleecker ER. Sequencing of the beta2 adrenergic receptor gene in the Puerto Ricans with asthma. Am J Respir Crit Care Med 2007; 175(A461).
37. Reihsaus E, Innis M, MacIntyre N, Liggett SB. Mutations in the gene encoding for the beta 2-adrenergic receptor in normal and asthmatic subjects. Am J Respir Cell Mol Biol 1993; 8(3): 334-339
38. Moore PE. Exploration of the beta2-adrenergic receptor regulatory regions: the next step in the holy grail of asthma pharmacogenetics research. Am J Physiol Lung Cell Mol Physiol 2008; 294(2): L187-9.
39. Dewar JC, Wilkinson J, Wheatley A, Thomas NS, Doull I, Morton N, et al. The glutamine 27 beta2-adrenoceptor polymorphism is associated with elevated IgE levels in asthmatic families. J Allergy Clin Immunol 1997; 100(2): 261-265 (Pubitemid 27349870)
40. Hall IP, Blakey JD, Al Balushi KA, Wheatley A, Sayers I, Pembrey ME, et al. Beta2-adrenoceptor polymorphisms and asthma from childhood to middle age in the British 1958 birth cohort: a genetic association study. Lancet 2006; 368(9537): 771-779
41. Israel E, Drazen JM, Liggett SB, Boushey HA, Cherniack RM, Chinchilli VM, et al. The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in asthma. Am J Respir Crit Care Med 2000; 162(1): 75-80.
42. Wechsler ME, Lehman E, Lazarus SC, Lemanske RF, Jr., Boushey HA, Deykin A, et al. beta-Adrenergic receptor polymorphisms and response to salmeterol. Am J Respir Crit Care Med 2006; 173(5): 519-526
43. Martinez FD, Graves PE, Baldini M, Solomon S, Erickson R. Association between genetic polymorphisms of the beta2-adrenoceptor and response to albuterol in children with and without a history of wheezing. J Clin Invest 1997; 100(12): 3184-3188 (Pubitemid 28022857)
44. Lima JJ, Thomason DB, Mohamed MH, Eberle LV, Self TH, Johnson JA. Impact of genetic polymorphisms of the beta2-adrenergic receptor on albuterol bronchodilator pharmacodynamics. Clin Pharmacol Ther 1999; 65(5): 519-525
45. Choudhry S, Ung N, Avila PC, Ziv E, Nazario S, Casal J, et al. Pharmacogenetic differences in response to albuterol between Puerto Ricans and Mexicans with asthma. Am J Respir Crit Care Med 2005; 171(6): 563-570 (Pubitemid 40365410)
46. Green SA, Turki J, Innis M, Liggett SB. Amino-terminal polymorphisms of the human beta 2-adrenergic receptor impart distinct agonist-promoted regulatory properties. Biochemistry 1994; 33(32): 9414-9419 (Pubitemid 24272896)
47. Green SA, Turki J, Bejarano P, Hall IP, Liggett SB. Influence of beta 2-adrenergic receptor genotypes on signal transduction in human airway smooth muscle cells. Am J Respir Cell Mol Biol 1995; 13(1): 25-33.
48. Martin AC, Zhang G, Rueter K, Khoo SK, Bizzintino J, Hayden CM, et al. Beta2-adrenoceptor polymorphisms predict response to beta2-agonists in children with acute asthma. J Asthma 2008; 45(5): 383-388 (Pubitemid 351882719)
49. Tsai HJ, Shaikh N, Kho JY, Battle N, Naqvi M, Navarro D, et al. Beta 2-adrenergic receptor polymorphisms: pharmacogenetic response to bronchodilator among African American asthmatics. Hum Genet 2006; 119(5): 547-557
50. Taylor DR, Epton MJ, Kennedy MA, Smith AD, Iles S, Miller AL, et al. Bronchodilator response in relation to beta2-adrenoceptor haplotype in patients with asthma. Am J Respir Crit Care Med 2005; 172(6): 700-703 (Pubitemid 41324224)
51. Drysdale CM, McGraw DW, Stack CB, Stephens JC, Judson RS, Nandabalan K, et al. Complex promoter and coding region beta 2-adrenergic receptor haplotypes alter receptor expression and predict in vivo responsiveness. Proc Natl Acad Sci USA 2000; 97(19): 10483-10488
52. Telleria JJ, Blanco-Quiros A, Muntion S, Antonio Garrote J, Arranz E, Armentia A, et al. Tachyphylaxis to beta2-agonists in Spanish asthmatic patients could be modulated by beta2-adrenoceptor gene polymorphisms. Respir Med 2006; 100(6): 1072-1078
53. Summerhill E, Leavitt SA, Gidley H, Parry R, Solway J, Ober C. beta(2)-adrenergic receptor Arg16/Arg16 genotype is associated with reduced lung function, but not with asthma, in the Hutterites. Am J Respir Crit Care Med 2000; 162(2 Pt 1): 599-602.
54. Dishy V, Sofowora GG, Xie HG, Kim RB, Byrne DW, Stein CM, et al. The effect of common polymorphisms of the beta2-adrenergic receptor on agonist-mediated vascular desensitization. N Engl J Med 2001; 345(14): 1030-1035 (Pubitemid 34940795)
55. Israel E, Chinchilli VM, Ford JG, Boushey HA, Cherniack R, Craig TJ, et al. Use of regularly scheduled albuterol treatment in asthma: genotype-stratified, randomised, placebo-controlled cross-over trial. Lancet 2004; 364(9444): 1505-1512 (Pubitemid 39410416)
56. Taylor DR, Drazen JM, Herbison GP, Yandava CN, Hancox RJ, Town GI. Asthma exacerbations during long term beta agonist use: influence of beta(2) adrenoceptor polymorphism. Thorax 2000; 55(9): 762-767
57. Haahtela T, Jarvinen M, Kava T, Kiviranta K, Koskinen S, Lehtonen K, et al. Comparison of a beta 2-agonist, terbutaline, with an inhaled corticosteroid, budesonide, in newly detected asthma. N Engl J Med 1991; 325(6): 388-392
58. National Asthma Education and Prevention Program. Expert Panel Report 2: Guidelines for the diagnosis and management of asthma. National Institutes of Health 1997.
59. Contopoulos-Ioannidis DG, Alexiou GA, Gouvias TC, Ioannidis JP. An empirical evaluation of multifarious outcomes in pharmacogenetics: beta-2 adrenoceptor gene polymorphisms in asthma treatment. Pharmacogenetics and Genomics 2006; 16(10): 705-711
60. Bleecker ER, Postma DS, Lawrance RM, Meyers DA, Ambrose HJ, Goldman M. Effect of ADRB2 polymorphisms on response to longacting beta2-agonist therapy: a pharmacogenetic analysis of two randomised studies. Lancet 2007; 370(9605): 2118-2125 (Pubitemid 350296302)
61. Green SA, Cole G, Jacinto M, Innis M, Liggett SB. A polymorphism of the human beta 2-adrenergic receptor within the fourth transmembrane domain alters ligand binding and functional properties of the receptor. J Biol Chem 1993; 268(31): 23116-23121 (Pubitemid 23328021)
62. Green SA, Rathz DA, Schuster AJ, Liggett SB. The Ile164 beta(2)-adrenoceptor polymorphism alters salmeterol exosite binding and conventional agonist coupling to G(s). Eur J Pharmacol 2001; 421(3): 141-147
63. Panebra A, Schwarb MR, Swift SM, Weiss ST, Bleecker ER, Hawkins GA, et al. Variable-length poly-C tract polymorphisms of the beta2-adrenergic receptor 3′-UTR alter expression and agonist regulation. Am J Physiol Lung Cell Mol Physiol 2008; 294(2): L190-5. (Pubitemid 351253356)
64. Tantisira KG, Small KM, Litonjua AA, Weiss ST, Liggett SB. Molecular properties and pharmacogenetics of a polymorphism of adenylyl cyclase type 9 in asthma: interaction between beta-agonist and corticosteroid pathways. Hum Mol Genet 2005; 14(12): 1671-1677
65. Poon AH, Tantisira KG, Litonjua AA, Lazarus R, Xu J, Lasky-Su J, et al. Association of corticotropin-releasing hormone receptor-2 genetic variants with acute bronchodilator response in asthma. Pharmacogenet Genomics 2008; 18(5): 373-382
66. Finney PA, Belvisi MG, Donnelly LE, Chuang TT, Mak JC, Scorer C, et al. Albuterol-induced downregulation of Gsalpha accounts for pulmonary beta(2)-adrenoceptor desensitization in vivo. J Clin Invest 2000; 106(1): 125-135 (Pubitemid 30437248)
67. Zimmermann N, King NE, Laporte J, Yang M, Mishra A, Pope SM, et al. Dissection of experimental asthma with DNA microarray analysis identifies arginase in asthma pathogenesis. J Clin Invest 2003; 111(12): 1863-1874 (Pubitemid 38057731)
68. Maarsingh H, Leusink J, Bos IS, Zaagsma J, Meurs H. Arginase strongly impairs neuronal nitric oxide-mediated airway smooth muscle relaxation in allergic asthma. Respir Res 2006; 7: 6. (Pubitemid 43250814)
69. Yang M, Rangasamy D, Matthaei KI, Frew AJ, Zimmmermann N, Mahalingam S, et al. Inhibition of arginase I activity by RNA interference attenuates IL-13-induced airways hyperresponsiveness. J Immunol 2006; 177(8): 5595-5603 (Pubitemid 44527634)
70. Chung F, Fabbri LM. Asthma. In: Wouters EFM, Ed.: Sheffield: ERS Journals Ltd. 2003.
71. Pignatti PF. Trends in pharmacogenomics of drugs used in the treatment of asthma. Pharmacol Res 2004; 49(4): 343-349
72. Barnes PJ, Grunstein, MM, Leff AR, Woolcock AJ. Asthma. Philadelphia: Lippincott-Raven 1997.
73. Umland SP, Schleimer RP, Johnston SL. Review of the molecular and cellular mechanisms of action of glucocorticoids for use in asthma. Pulm Pharmacol Ther 2002; 15(1): 35-50. (Pubitemid 34971552)
74. Emala CW, Clancy J, Hirshman CA. Glucocorticoid treatment decreases muscarinic receptor expression in canine airway smooth muscle. Am J Physiol 1997; 272(4 Pt 1): L745-51. (Pubitemid 27197847)
75. Szefler SJ, Leung DY. Glucocorticoid-resistant asthma: pathogenesis and clinical implications for management. Eur Respir J 1997; 10(7): 1640-1647 (Pubitemid 27311085)
76. Mak JC, Nishikawa M, Barnes PJ. Glucocorticosteroids increase beta 2-adrenergic receptor transcription in human lung. Am J Physiol 1995; 268(1 Pt 1): L41-6.
77. Roth M, Johnson PR, Rudiger JJ, King GG, Ge Q, Burgess JK, et al. Interaction between glucocorticoids and beta2 agonists on bronchial airway smooth muscle cells through synchronised cellular signalling. Lancet 2002; 360(9342): 1293-1299 (Pubitemid 35284621)
78. Hirst SJ, Lee TH. Airway smooth muscle as a target of glucocorticoid action in the treatment of asthma. Am J Respir Crit Care Med 1998; 158(5 Pt 3): S201-6.
79. Eickelberg O, Roth M, Lorx R, Bruce V, Rudiger J, Johnson M, et al. Ligand-independent activation of the glucocorticoid receptor by beta2-adrenergic receptor agonists in primary human lung fibroblasts and vascular smooth muscle cells. J Biol Chem 1999; 274(2): 1005-1010 (Pubitemid 129535264)
80. Sharek PJ, Bergman DA. The effect of inhaled steroids on the linear growth of children with asthma: a meta-analysis. Pediatrics 2000; 106(1): E8.
81. Patel L, Wales JK, Kibirige MS, Massarano AA, Couriel JM, Clayton PE. Symptomatic adrenal insufficiency during inhaled corticosteroid treatment. Arch Dis Child 2001; 85(4): 330-334 (Pubitemid 32929601)
82. Casale TB, Nelson HS, Stricker WE, Raff H, Newman KB. Suppression of hypothalamic-pituitary-adrenal axis activity with inhaled flunisolide and fluticasone propionate in adult asthma patients. Ann Allergy Asthma Immunol 2001; 87(5): 379-385 (Pubitemid 33063936)
83. Israel E, Banerjee TR, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. N Engl J Med 2001; 345(13): 941-947 (Pubitemid 34940809)
84. Isaksson M. Skin reactions to inhaled corticosteroids. Drug Saf 2001; 24(5): 369-373
85. Jick SS, Vasilakis-Scaramozza C, Maier WC. The risk of cataract among users of inhaled steroids. Epidemiology 2001; 12(2): 229-234 (Pubitemid 32167759)
86. Schwartz JT, Reuling FH, Feinleib M, Garrison RJ, Collie DJ. Twin heritability study of the effect of corticosteroids on intraocular pressure. J Med Genet 1972; 9(2): 137-143
87. Corrigan CJ, Brown PH, Barnes NC, Szefler SJ, Tsai JJ, Frew AJ, et al. Glucocorticoid resistance in chronic asthma. Glucocorticoid pharmacokinetics, glucocorticoid receptor characteristics, and inhibition of peripheral blood T cell proliferation by glucocorticoids in vitro. Am Rev Respir Dis 1991; 144(5): 1016-1025
88. Ito K, Chung KF, Adcock IM. Update on glucocorticoid action and resistance. J Allergy Clin Immunol 2006; 117(3): 522-543
89. Chan MT, Leung DY, Szefler SJ, Spahn JD. Difficult-to-control asthma: clinical characteristics of steroid-insensitive asthma. J Allergy Clin Immunol 1998; 101(5): 594-601. (Pubitemid 28228301)
90. Leung DY, Spahn JD, Szefler SJ. Steroid-unresponsive asthma. Semin Respir Crit Care Med 2002; 23(4): 387-398
91. Tantisira KG, Lake S, Silverman ES, Palmer LJ, Lazarus R, Silverman EK, et al. Corticosteroid pharmacogenetics: association of sequence variants in CRHR1 with improved lung function in asthmatics treated with inhaled corticosteroids. Hum Mol Genet 2004; 13(13): 1353-1359 (Pubitemid 38961642)
92. Levene RZ, Schwartz B, Workman PL. Heritability of plasma cortisol. Arch Ophthalmol 1972; 87(4): 389-391
93. Meikle AW, Stringham JD, Woodward MG, Bishop DT. Heritability of variation of plasma cortisol levels. Metabolism 1988; 37(6): 514-517 (Pubitemid 18150114)
94. Kirschbaum C, Wust S, Faig HG, Hellhammer DH. Heritability of cortisol responses to human corticotropin-releasing hormone, ergometry, and psychological stress in humans. J Clin Endocrinol Metab 1992; 75(6): 1526-1530 (Pubitemid 23001416)
95. Inglis GC, Ingram MC, Holloway CD, Swan L, Birnie D, Hillis WS, et al. Familial pattern of corticosteroids and their metabolism in adult human subjects - the Scottish Adult Twin Study. J Clin Endocrinol Metab 1999; 84(11): 4132-4137 (Pubitemid 30644205)
96. Wust S, Federenko I, Hellhammer DH, Kirschbaum C. Genetic factors, perceived chronic stress, and the free cortisol response to awakening. Psychoneuroendocrinology 2000; 25(7): 707-720 (Pubitemid 30628432)
97. Ober C, Abney M, McPeek MS. The genetic dissection of complex traits in a founder population. Am J Hum Genet 2001; 69(5): 1068-1079 (Pubitemid 33015822)
98. Bartels M, Van den Berg M, Sluyter F, Boomsma DI, de Geus EJ. Heritability of cortisol levels: review and simultaneous analysis of twin studies. Psychoneuroendocrinology 2003; 28(2): 121-137 (Pubitemid 36044074)
99. Adcock IMaL SJ. Mechanisms of Steroid Action and Resistance in Inflammation. J Endocrinol 2003; 178: 347-355
100. Sousa AR, Lane SJ, Cidlowski JA, Staynov DZ, Lee TH. Glucocorticoid resistance in asthma is associated with elevated in vivo expression of the glucocorticoid receptor beta-isoform. J Allergy Clin Immunol 2000; 105(5): 943-950
101. Bray PJ, Cotton RG. Variations of the human glucocorticoid receptor gene (NR3C1): pathological and in vitro mutations and polymorphisms. Hum Mutat 2003; 21(6): 557-568
102. Hurley DM, Accili D, Stratakis CA, Karl M, Vamvakopoulos N, Rorer E, et al. Point mutation causing a single amino acid substitution in the hormone binding domain of the glucocorticoid receptor in familial glucocorticoid resistance. J Clin Invest 1991; 87(2): 680-686
103. Malchoff DM, Brufsky A, Reardon G, McDermott P, Javier EC, Bergh CH, et al. A mutation of the glucocorticoid receptor in primary cortisol resistance. J Clin Invest 1993; 91(5): 1918-1925 (Pubitemid 23141460)
104. Leung DY, Martin RJ, Szefler SJ, Sher ER, Ying S, Kay AB, et al. Dysregulation of interleukin 4, interleukin 5, and interferon gamma gene expression in steroid-resistant asthma. J Exp Med 1995; 181(1): 33-40.
105. Tantisira KG, Lazarus R, Litonjua AA, Klanderman B, Weiss ST. Chromosome 17: association of a large inversion polymorphism with corticosteroid response in asthma. Pharmacogenet Genomics 2008; 18(8): 733-737
106. Finotto S, Neurath MF, Glickman JN, Qin S, Lehr HA, Green FH, et al. Development of spontaneous airway changes consistent with human asthma in mice lacking T-bet. Science 2002; 295(5553): 336-338 (Pubitemid 34074365)
107. Tantisira KG, Hwang ES, Raby BA, Silverman ES, Lake SL, Richter BG, et al. TBX21: a functional variant predicts improvement in asthma with the use of inhaled corticosteroids. Proc Natl Acad Sci USA 2004; 101(52): 18099-18104
108. Tantisira KG, Silverman ES, Mariani TJ, Xu J, Richter BG, Klanderman BJ, et al. FCER2: a pharmacogenetic basis for severe exacerbations in children with asthma. J Allergy Clin Immunol 2007; 120(6): 1285-1291 (Pubitemid 350216603)
109. Hakonarson H, Bjornsdottir US, Halapi E, Bradfield J, Zink F, Mouy M, et al. Profiling of genes expressed in peripheral blood mononuclear cells predicts glucocorticoid sensitivity in asthma patients. Proc Natl Acad Sci USA 2005; 102(41): 14789-14794 (Pubitemid 41457134)
110. Chanarin N, Johnston SL. Leukotrienes as a target in asthma therapy. Drugs 1994; 47(1): 12-24.
111. Drazen JM. Leukotrienes in asthma and rhinitis. In: Busse W, Holgate ST, ed. Asthma and Rhinitis. Oxford: Blackwell Scientific Publications 1995: 838-850
112. Lima JJ. Treatment heterogeneity in asthma: genetics of response to leukotriene modifiers. Mol Diagn Ther 2007; 11(2): 97-104.
113. Drazen JM, Yandava CN, Dube L, Szczerback N, Hippensteel R, Pillari A, et al. Pharmacogenetic association between ALOX5 promoter genotype and the response to anti-asthma treatment. Nat Genet 1999; 22(2): 168-170 (Pubitemid 29264811)
114. Lima JJ, Zhang S, Grant A, Shao L, Tantisira KG, Allayee H, et al. Influence of leukotriene pathway polymorphisms on response to montelukast in asthma. Am J Respir Crit Care Med 2006; 173(4): 379-385 (Pubitemid 43228324)
115. Telleria JJ, Blanco-Quiros A, Varillas D, Armentia A, Fernandez-Carvajal I, Jesus Alonso M, et al. ALOX5 promoter genotype and response to montelukast in moderate persistent asthma. Respir Med 2008; 102(6): 857-861
116. Klotsman M, York TP, Pillai SG, Vargas-Irwin C, Sharma SS, van den Oord EJ, et al. Pharmacogenetics of the 5-lipoxygenase biosynthetic pathway and variable clinical response to montelukast. Pharmacogenet Genomics 2007; 17(3): 189-196 (Pubitemid 46668003)
117. Sayers I, Barton S, Rorke S, Beghe B, Hayward B, Van Eerdewegh P, et al. Allelic association and functional studies of promoter polymorphism in the leukotriene C4 synthase gene (LTC4S) in asthma. Thorax 2003; 58(5): 417-424 (Pubitemid 36560945)
118. Sampson AP, Siddiqui S, Buchanan D, Howarth PH, Holgate ST, Holloway JW, et al. Variant LTC(4) synthase allele modifies cysteinyl leukotriene synthesis in eosinophils and predicts clinical response to zafirlukast. Thorax 2000; 55 Suppl 2: S28-31.
119. Anderson W, Kalgerg C, Edwards L, Fling M, Binnie C, Nguyen Q, et al. Effects of polymorphisms in the promoter region of 5-lipoxygenase and LTC$ synthase on the clinical response to zafirlukast and fluticasone. Eur Respir J 2000; 16(Suppl B): 183s.
120. Mougey EB, Feng H, Castro M, Irvin C, Lima J. Transporter mediated absorption of montelukast in a CACO-2 model system. Clin Pharmacol Ther 2008; 83(S67).
121. Revicki DA, Leidy NK, Brennan-Diemer F, Sorensen S, Togias A. Integrating patient preferences into health outcomes assessment: the multiattribute Asthma Symptom Utility Index. Chest 1998; 114(4): 998-1007. (Pubitemid 28495893)
122. ALA A. Clinical trial of low-dose theophilline and montelukast in patients with poorly controlled asthma. Am J Respir Crit Care Med 2007; 175(3): 235-242
123. Mougey EB, Feng H, Irvin C, Lima J. Montelukast plasma concentration associates with a common SNP on SLCO2B1. Clin Pharmacol Ther 2008; 83(S67).
124. Weiss ST, Litonjua AA, Lange C, Lazarus R, Liggett SB, Bleecker ER, et al. Overview of the pharmacogenetics of asthma treatment. Pharmacogenomics J 2006; 6(5): 311-326
125. Litonjua AA, Lasky-Su J, Schneiter K, Tantisira KG, Lazarus R, Klanderman B, et al. ARG1 is a novel bronchodilator response gene: screening and replication in four asthma cohorts. Am J Respir Crit Care Med 2008; 178(7): 688-694
126. Van Steen K, McQueen MB, Herbert A, Raby B, Lyon H, Demeo DL, et al. Genomic screening and replication using the same data set in family-based association testing. Nat Genet 2005; 37(7): 683-691 (Pubitemid 41754884)
127. Herbert A, Gerry NP, McQueen MB, Heid IM, Pfeufer A, Illig T, et al. A common genetic variant is associated with adult and childhood obesity. Science 2006; 312(5771): 279-283
128. Lyon HN, Emilsson V, Hinney A, Heid IM, Lasky-Su J, Zhu X, et al. The association of a SNP upstream of INSIG2 with body mass index is reproduced in several but not all cohorts. PLoS Genet 2007; 3(4): e61. (Pubitemid 46683478)
129. Lasky-Su J, Lyon HN, Emilsson V, Heid IM, Molony C, Raby BA, et al. On the replication of genetic associations: timing can be everything! Am J Hum Genet 2008; 82(4): 849-858
130. Cheung VG, Conlin LK, Weber TM, Arcaro M, Jen KY, Morley M, et al. Natural variation in human gene expression assessed in lymphoblastoid cells. Nat Genet 2003; 33(3): 422-425 (Pubitemid 36278862)
131. Liu MT, Chen YR, Chen SC, Hu CY, Lin CS, Chang YT, et al. Epstein-Barr virus latent membrane protein 1 induces micronucleus formation, represses DNA repair and enhances sensitivity to DNA-damaging agents in human epithelial cells. Oncogene 2004; 23(14): 2531-2539
132. Feng WH, Hong G, Delecluse HJ, Kenney SC. Lytic induction therapy for Epstein-Barr virus-positive B-cell lymphomas. J Virol 2004; 78(4): 1893-1902 (Pubitemid 38176721)
133. Shu Y, Sheardown SA, Brown C, Owen RP, Zhang S, Castro RA, et al. Effect of genetic variation in the organic cation transporter 1 (OCT1) on metformin action. J Clin Invest 2007; 117(5): 1422-1431 (Pubitemid 46718430)
134. Weidinger S, Gieger C, Rodriguez E, Baurecht H, Mempel M, Klopp N, et al. Genome-wide scan on total serum IgE levels identifies FCER1A as novel susceptibility locus. PLoS Genet 2008; 4(8): e1000166.
135. Burkhardt R, Kenny EE, Lowe JK, Birkeland A, Josowitz R, Noel M, et al. Common SNPs in HMGCR in micronesians and whites associated with LDL-cholesterol levels affect alternative splicing of exon13. Arterioscler Thromb Vasc Biol 2008; 28(11): 2078-2084
136. Rountree MR, Bachman KE, Herman JG, Baylin SB. DNA methylation, chromatin inheritance, and cancer. Oncogene 2001; 20(24): 3156-3165 (Pubitemid 32553571)
137. Razin A. CpG methylation, chromatin structure and gene silencing - a three-way connection. EMBO J 1998; 17(17): 4905-4908 (Pubitemid 28408457)
138. Razin A, Szyf M. DNA methylation patterns. Formation and function. Biochimica et biophysica acta 1984; 782(4): 331-342
139. Cooney CA, Dave AA, Wolff GL. Maternal methyl supplements in mice affect epigenetic variation and DNA methylation of offspring. J Nutr 2002; 132(8 Suppl): 2393S-400S.
140. Waterland RA, Jirtle RL. Transposable elements: targets for early nutritional effects on epigenetic gene regulation. Mol Cell Biol 2003; 23(15): 5293-5300
141. Dolinoy DC, Weidman JR, Jirtle RL. Epigenetic gene regulation: linking early developmental environment to adult disease. Reprod Toxicol 2007; 23(3): 297-307.
142. Tang WY, Ho SM. Epigenetic reprogramming and imprinting in origins of disease. Rev Endocr Metab Disord 2007; 8(2): 173-182
143. Hollingsworth JW, Maruoka S, Boon K, Garantziotis S, Li Z, Tomfohr J, et al. In utero supplementation with methyl donors enhances allergic airway disease in mice. J Clin Invest 2008; 118(10): 3462-3469
144. Liu J, Ballaney M, Al-alem U, Quan C, Jin X, Perera F, et al. Combined inhaled diesel exhaust particles and allergen exposure alter methylation of T helper genes and IgE production in vivo. Toxicol Sci 2008; 102(1): 76-81. (Pubitemid 351265126)
145. Kwon NH, Kim JS, Lee JY, Oh MJ, Choi DC. DNA methylation and the expression of IL-4 and IFN-gamma promoter genes in patients with bronchial asthma. J Clin Immunol 2008; 28(2): 139-146
146. Ito K, Caramori G, Lim S, Oates T, Chung KF, Barnes PJ, et al. Expression and activity of histone deacetylases in human asthmatic airways. Am J Respir Crit Care Med 2002; 166(3): 392-396 (Pubitemid 34864433)
147. Uhl J, Klan N, Rose M, Entian KD, Werz O, Steinhilber D. The 5-lipoxygenase promoter is regulated by DNA methylation. J Biol Chem 2002; 277(6): 4374-4379 (Pubitemid 34975655)
148. Stranger BE, Forrest MS, Dunning M, Ingle CE, Beazley C, Thorne N, et al. Relative impact of nucleotide and copy number variation on gene expression phenotypes. Science 2007; 315(5813): 848-853 (Pubitemid 46255837)
149. Townson JR, Barcellos LF, Nibbs RJ. Gene copy number regulates the production of the human chemokine CCL3-L1. Eur J Immunol 2002; 32(10): 3016-3026
150. Colombo G, Terzano C, Colombo P, Petroianni A, Ricci A, Buttini F. Methacholine dry powder inhaler as a new tool for bronchial challenge test. Int J Pharm 2008; 352(1-2): 165-171 (Pubitemid 351273930)
151. Morphy R, Rankovic Z. Designing multiple ligands - medicinal chemistry strategies and challenges. Curr Pharm Des 2009; 15(6): 587-600.
152. Viola M, Quaratino D, Gaeta F, Rumi G, Caruso C, Romano A. Cross-reactive reactions to nonsteroidal anti-inflammatory drugs. Curr Pharm Des 2008; 14(27): 2826-2832